SCHEMBL3521139

SCHEMBL3521139

COC(=O)c1c(OC)c(Br)cc2nc(-c3nccs3)cnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38
HPGD P15428 1/20 0.37
TACR3 P29371 1/20 0.37
ALDH1A1 P00352 1/20 0.36
PPARG P37231 1/20 0.36
MAPK10 P53779 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
SMPD3 Q9NY59 1/20 0.36
CYP1A1 P04798 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP1B1 Q16678 2/20 0.35
SYK P43405 2/20 0.34
SRC P12931 1/20 0.34
ZAP70 P43403 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
PKMYT1 Q99640 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518822 0.88 HPGD (0.38) TSHRHPGDTACR3SMPD3CYP1A1
SCHEMBL3521337 0.82 MEN1 (0.47) TSHRHPGDTACR3ALDH1A1PPARG
SCHEMBL3525976 0.79 CTSA (0.39) HPGDTACR3CYP1A1CYP1A2CYP1B1
SCHEMBL3521940 0.78 HPGD (0.41) HPGDTACR3KMT2ASMPD3CYP3A4
SCHEMBL3523124 0.77 POLB (0.39) TSHRHPGDALDH1A1MAPTLMNA
SCHEMBL3518253 0.76 PDGFRB (0.39) HPGDKMT2ARAB9A
SCHEMBL3521595 0.75 MAPT (0.37) TSHRHPGDALDH1A1MAPK10KMT2A
SCHEMBL3537880 0.73 EGLN3 (0.43) HPGDTACR3
SCHEMBL3532359 0.73 LMNA (0.37) HPGDTACR3ALDH1A1NPSR1CYP3A4
SCHEMBL3519874 0.71 MEN1 (0.49) TSHRHPGDTACR3ALDH1A1MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 TSHR 2760/4885HPGD 51/4885TACR3 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.